Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calithera Biosciences Inc CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Recent & Breaking News (GREY:CALA)

Calithera Biosciences' CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conference

GlobeNewswire October 7, 2020

Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 2, 2020

Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer

GlobeNewswire September 24, 2020

Calithera to Participate in Multiple Upcoming Investor Conferences

GlobeNewswire September 4, 2020

Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 2, 2020

Calithera Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

GlobeNewswire August 10, 2020

Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 3, 2020

Calithera Biosciences to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

GlobeNewswire July 28, 2020

Calithera Biosciences Appoints Scott Garland to Board of Directors

GlobeNewswire July 14, 2020

Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

GlobeNewswire July 13, 2020

Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 2, 2020

Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 2, 2020

Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting

GlobeNewswire May 29, 2020

Calithera to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 27, 2020

Calithera Biosciences Reports First Quarter 2020 Financial Results and Recent Highlights

GlobeNewswire May 7, 2020

Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 6, 2020

Calithera Biosciences to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

GlobeNewswire May 1, 2020

Calithera Biosciences Announces Telaglenastat KEAPSAKE Trial in Progress Abstract Accepted for Presentation at ASCO20 Virtual Annual Meeting

GlobeNewswire April 30, 2020

Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

GlobeNewswire April 20, 2020

Calithera Biosciences, Inc. Prices Public Offering of 5,000,000 shares of Common Stock

GlobeNewswire April 16, 2020